So-Soo-Yoo®

AngioGenex files patent about first small molecule Id-inhibitors AngioGenex Inc.

Preliminary clinical outcomes suggest that it gets the potential to identify the current presence of Id proteins at an early on stage of tumor advancement enabling early medical intervention; it could also be beneficial to either stick to the course of therapy or to determine whether there is a recurrence of disease.. AngioGenex files patent about first small molecule Id-inhibitors AngioGenex Inc. Has determined and filed a patent software on little molecules that are potent inhibitors of the Id proteins. ‘The identification of the lead molecules and the filing of the patent constitute main milestones in the business’s goal to build up orally active anti-cancer drugs,’ said Dr. Richard Salvador, President and CEO, and the former global head of Preclinical Development at Hoffmann La Roche, Inc.Cognizant's development underscores the strong preference that payers show for service providers with large and balanced portfolio of offerings. Related StoriesReducing medical center readmissions through Transitional Treatment: an interview with Rani KhetarpalOJ Bio at Medica 2015 – Point of Treatment diagnostics' function in reducing antibiotics prescribingSurgical startup seeks financing to build virtual actuality training library This reputation by Everest Group underscores Cognizant's distinctive ability to enable payer organizations to address long-term secular shifts in the continuing business, regulatory and technology environments, said Krish Venkat, Executive Vice President of Cognizant's Healthcare and Lifestyle Sciences practice.